prompt
stringlengths 2.15k
5.36k
| title
stringclasses 394
values | abstract
stringclasses 394
values | head_entity
dict | title_entity
dict | candidate_relation_list
sequencelengths 3
7
| label
stringclasses 8
values |
|---|---|---|---|---|---|---|
<s>[INST]<<SYS>>
Your task is to determine the relationship between a gene or protein Hepatocyte nuclear factor-6 and a disease type II diabetes in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' here means that the relation between a gene and a disease is direct and increases the likelihood of the disease. This includes cases where too much protein causes the disease, removing the gene prevents the disease, or a side effect from the protein or drug results in the disease.
'Negative_Correlation' indicates that when a protein (or gene) is present, it helps to treat or prevent a disease. Conversely, the absence of this protein or the deactivation of its gene can lead to the disease.
'Association' is used to describe relation that don't clearly fall under categories like positive or negative correlation, or when the nature of the relation lack a clear description.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[Hepatocyte nuclear factor-6,GeneOrGeneProduct]' and '[type II diabetes,DiseaseOrPhenotypicFeature]'.
- Title of the Paper: Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion.
- Abstract of the Paper: [The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several genes involved in the pathogenesis of maturity-onset diabetes of the young. We therefore tested the hypothesis that variability in the HNF-6 gene is associated with subsets of Type II (non-insulin-dependent) diabetes mellitus and estimates of insulin secretion in glucose tolerant subjects. We cloned the coding region as well as the intron-exon boundaries of the HNF-6 gene. We then examined them on genomic DNA in six MODY probands without mutations in the MODY1, MODY3 and MODY4 genes and in 54 patients with late-onset Type II diabetes by combined single strand conformational polymorphism-heteroduplex analysis followed by direct sequencing of identified variants. An identified missense variant was examined in association studies and genotype-phenotype studies. We identified two silent and one missense (Pro75 Ala) variant. In an association study the allelic frequency of the Pro75Ala polymorphism was 3.2% (95% confidence interval, 1.9-4.5) in 330 patients with Type II diabetes mellitus compared with 4.2% (2.4-6.0) in 238 age-matched glucose tolerant control subjects. Moreover, in studies of 238 middle-aged glucose tolerant subjects, of 226 glucose tolerant offspring of Type II diabetic patients and of 367 young healthy subjects, the carriers of the polymorphism did not differ from non-carriers in glucose induced serum insulin or C-peptide responses. Mutations in the coding region of the HNF-6 gene are not associated with Type II diabetes or with changes in insulin responses to glucose among the Caucasians examined.]
Identify how '[Hepatocyte nuclear factor-6,GeneOrGeneProduct]' and '[type II diabetes,DiseaseOrPhenotypicFeature]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Association</s> | Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion. | The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several genes involved in the pathogenesis of maturity-onset diabetes of the young. We therefore tested the hypothesis that variability in the HNF-6 gene is associated with subsets of Type II (non-insulin-dependent) diabetes mellitus and estimates of insulin secretion in glucose tolerant subjects. We cloned the coding region as well as the intron-exon boundaries of the HNF-6 gene. We then examined them on genomic DNA in six MODY probands without mutations in the MODY1, MODY3 and MODY4 genes and in 54 patients with late-onset Type II diabetes by combined single strand conformational polymorphism-heteroduplex analysis followed by direct sequencing of identified variants. An identified missense variant was examined in association studies and genotype-phenotype studies. We identified two silent and one missense (Pro75 Ala) variant. In an association study the allelic frequency of the Pro75Ala polymorphism was 3.2% (95% confidence interval, 1.9-4.5) in 330 patients with Type II diabetes mellitus compared with 4.2% (2.4-6.0) in 238 age-matched glucose tolerant control subjects. Moreover, in studies of 238 middle-aged glucose tolerant subjects, of 226 glucose tolerant offspring of Type II diabetic patients and of 367 young healthy subjects, the carriers of the polymorphism did not differ from non-carriers in glucose induced serum insulin or C-peptide responses. Mutations in the coding region of the HNF-6 gene are not associated with Type II diabetes or with changes in insulin responses to glucose among the Caucasians examined. | {
"name": "Hepatocyte nuclear factor-6",
"type": "GeneOrGeneProduct"
} | {
"name": "type II diabetes",
"type": "DiseaseOrPhenotypicFeature"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Association |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a chemical glucose and a gene or protein insulin in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Bind', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means that a chemical leads to higher gene expression, or higher gene expression increases sensitivity to the chemical, or a gene variant exacerbates the chemical's side effects, or a gene causes an over-response to the chemical, or there is a positive interaction between two genes in any manner.
'Negative_Correlation' indicates that a chemical leads to reduced gene expression, or higher gene expression results in decreased sensitivity or resistance to the chemical, or a gene variant offers protection against the chemical's adverse effects, or a gene contributes to resistance against the chemical, or there exists a negative interaction between two genes in any form.
'Bind' means that a chemical either connects to a gene's promoter region or a protein acts as a receptor for that chemical.
'Association' is used to describe relation that don't clearly fall under categories like positive correlation, negative correlation and bind , or when the nature of the relation lack a clear description.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[glucose,ChemicalEntity]' and '[insulin,GeneOrGeneProduct]'.
- Title of the Paper: Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion.
- Abstract of the Paper: [The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several genes involved in the pathogenesis of maturity-onset diabetes of the young. We therefore tested the hypothesis that variability in the HNF-6 gene is associated with subsets of Type II (non-insulin-dependent) diabetes mellitus and estimates of insulin secretion in glucose tolerant subjects. We cloned the coding region as well as the intron-exon boundaries of the HNF-6 gene. We then examined them on genomic DNA in six MODY probands without mutations in the MODY1, MODY3 and MODY4 genes and in 54 patients with late-onset Type II diabetes by combined single strand conformational polymorphism-heteroduplex analysis followed by direct sequencing of identified variants. An identified missense variant was examined in association studies and genotype-phenotype studies. We identified two silent and one missense (Pro75 Ala) variant. In an association study the allelic frequency of the Pro75Ala polymorphism was 3.2% (95% confidence interval, 1.9-4.5) in 330 patients with Type II diabetes mellitus compared with 4.2% (2.4-6.0) in 238 age-matched glucose tolerant control subjects. Moreover, in studies of 238 middle-aged glucose tolerant subjects, of 226 glucose tolerant offspring of Type II diabetic patients and of 367 young healthy subjects, the carriers of the polymorphism did not differ from non-carriers in glucose induced serum insulin or C-peptide responses. Mutations in the coding region of the HNF-6 gene are not associated with Type II diabetes or with changes in insulin responses to glucose among the Caucasians examined.]
Identify how '[glucose,ChemicalEntity]' and '[insulin,GeneOrGeneProduct]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Bind', 'Association']. [/INST]Positive_Correlation</s> | Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion. | The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several genes involved in the pathogenesis of maturity-onset diabetes of the young. We therefore tested the hypothesis that variability in the HNF-6 gene is associated with subsets of Type II (non-insulin-dependent) diabetes mellitus and estimates of insulin secretion in glucose tolerant subjects. We cloned the coding region as well as the intron-exon boundaries of the HNF-6 gene. We then examined them on genomic DNA in six MODY probands without mutations in the MODY1, MODY3 and MODY4 genes and in 54 patients with late-onset Type II diabetes by combined single strand conformational polymorphism-heteroduplex analysis followed by direct sequencing of identified variants. An identified missense variant was examined in association studies and genotype-phenotype studies. We identified two silent and one missense (Pro75 Ala) variant. In an association study the allelic frequency of the Pro75Ala polymorphism was 3.2% (95% confidence interval, 1.9-4.5) in 330 patients with Type II diabetes mellitus compared with 4.2% (2.4-6.0) in 238 age-matched glucose tolerant control subjects. Moreover, in studies of 238 middle-aged glucose tolerant subjects, of 226 glucose tolerant offspring of Type II diabetic patients and of 367 young healthy subjects, the carriers of the polymorphism did not differ from non-carriers in glucose induced serum insulin or C-peptide responses. Mutations in the coding region of the HNF-6 gene are not associated with Type II diabetes or with changes in insulin responses to glucose among the Caucasians examined. | {
"name": "glucose",
"type": "ChemicalEntity"
} | {
"name": "insulin",
"type": "GeneOrGeneProduct"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Bind",
"Association"
] | Positive_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a chemical glucose and a disease Type II diabetes mellitus in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means there's a direct link between a chemical and a disease. This includes cases where the chemical causes the disease, higher doses of the chemical increase disease risk, the disease raises the chemical's level in the body, there's a direct positive link between the chemical's level and disease risk, or exposure to the chemical during development affects disease susceptibility later on.
'Negative_Correlation' means there's an inverse relation between a chemical substance and a disease. This includes situations where the chemical or drug is used to treat the disease, the presence of the disease lowers the level of the chemical in the body, or the chemical or drug reduces the likelihood of the disease.
'Association' is used to describe relation that don't clearly fall under categories like positive or negative correlation, or when the nature of the relation lack a clear description.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[glucose,ChemicalEntity]' and '[Type II diabetes mellitus,DiseaseOrPhenotypicFeature]'.
- Title of the Paper: Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion.
- Abstract of the Paper: [The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several genes involved in the pathogenesis of maturity-onset diabetes of the young. We therefore tested the hypothesis that variability in the HNF-6 gene is associated with subsets of Type II (non-insulin-dependent) diabetes mellitus and estimates of insulin secretion in glucose tolerant subjects. We cloned the coding region as well as the intron-exon boundaries of the HNF-6 gene. We then examined them on genomic DNA in six MODY probands without mutations in the MODY1, MODY3 and MODY4 genes and in 54 patients with late-onset Type II diabetes by combined single strand conformational polymorphism-heteroduplex analysis followed by direct sequencing of identified variants. An identified missense variant was examined in association studies and genotype-phenotype studies. We identified two silent and one missense (Pro75 Ala) variant. In an association study the allelic frequency of the Pro75Ala polymorphism was 3.2% (95% confidence interval, 1.9-4.5) in 330 patients with Type II diabetes mellitus compared with 4.2% (2.4-6.0) in 238 age-matched glucose tolerant control subjects. Moreover, in studies of 238 middle-aged glucose tolerant subjects, of 226 glucose tolerant offspring of Type II diabetic patients and of 367 young healthy subjects, the carriers of the polymorphism did not differ from non-carriers in glucose induced serum insulin or C-peptide responses. Mutations in the coding region of the HNF-6 gene are not associated with Type II diabetes or with changes in insulin responses to glucose among the Caucasians examined.]
Identify how '[glucose,ChemicalEntity]' and '[Type II diabetes mellitus,DiseaseOrPhenotypicFeature]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Association</s> | Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion. | The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several genes involved in the pathogenesis of maturity-onset diabetes of the young. We therefore tested the hypothesis that variability in the HNF-6 gene is associated with subsets of Type II (non-insulin-dependent) diabetes mellitus and estimates of insulin secretion in glucose tolerant subjects. We cloned the coding region as well as the intron-exon boundaries of the HNF-6 gene. We then examined them on genomic DNA in six MODY probands without mutations in the MODY1, MODY3 and MODY4 genes and in 54 patients with late-onset Type II diabetes by combined single strand conformational polymorphism-heteroduplex analysis followed by direct sequencing of identified variants. An identified missense variant was examined in association studies and genotype-phenotype studies. We identified two silent and one missense (Pro75 Ala) variant. In an association study the allelic frequency of the Pro75Ala polymorphism was 3.2% (95% confidence interval, 1.9-4.5) in 330 patients with Type II diabetes mellitus compared with 4.2% (2.4-6.0) in 238 age-matched glucose tolerant control subjects. Moreover, in studies of 238 middle-aged glucose tolerant subjects, of 226 glucose tolerant offspring of Type II diabetic patients and of 367 young healthy subjects, the carriers of the polymorphism did not differ from non-carriers in glucose induced serum insulin or C-peptide responses. Mutations in the coding region of the HNF-6 gene are not associated with Type II diabetes or with changes in insulin responses to glucose among the Caucasians examined. | {
"name": "glucose",
"type": "ChemicalEntity"
} | {
"name": "Type II diabetes mellitus",
"type": "DiseaseOrPhenotypicFeature"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Association |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a gene or protein type II Ca2+-dependent lectin and a chemical mannose in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Bind', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means that a chemical leads to higher gene expression, or higher gene expression increases sensitivity to the chemical, or a gene variant exacerbates the chemical's side effects, or a gene causes an over-response to the chemical, or there is a positive interaction between two genes in any manner.
'Negative_Correlation' indicates that a chemical leads to reduced gene expression, or higher gene expression results in decreased sensitivity or resistance to the chemical, or a gene variant offers protection against the chemical's adverse effects, or a gene contributes to resistance against the chemical, or there exists a negative interaction between two genes in any form.
'Bind' means that a chemical either connects to a gene's promoter region or a protein acts as a receptor for that chemical.
'Association' is used to describe relation that don't clearly fall under categories like positive correlation, negative correlation and bind , or when the nature of the relation lack a clear description.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[type II Ca2+-dependent lectin,GeneOrGeneProduct]' and '[mannose,ChemicalEntity]'.
- Title of the Paper: Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules.
- Abstract of the Paper: [We have identified a type II Ca2+-dependent lectin displaying mannose-binding specificity, exclusively expressed by Langerhans cells (LC), and named Langerin. LC are uniquely characterized by Birbeck granules (BG), which are organelles consisting of superimposed and zippered membranes. Here, we have shown that Langerin is constitutively associated with BG and that antibody to Langerin is internalized into these structures. Remarkably, transfection of Langerin cDNA into fibroblasts created a compact network of membrane structures with typical features of BG. Langerin is thus a potent inducer of membrane superimposition and zippering leading to BG formation. Our data suggest that induction of BG is a consequence of the antigen-capture function of Langerin, allowing routing into these organelles and providing access to a nonclassical antigen-processing pathway.]
Identify how '[type II Ca2+-dependent lectin,GeneOrGeneProduct]' and '[mannose,ChemicalEntity]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Bind', 'Association']. [/INST]Bind</s> | Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. | We have identified a type II Ca2+-dependent lectin displaying mannose-binding specificity, exclusively expressed by Langerhans cells (LC), and named Langerin. LC are uniquely characterized by Birbeck granules (BG), which are organelles consisting of superimposed and zippered membranes. Here, we have shown that Langerin is constitutively associated with BG and that antibody to Langerin is internalized into these structures. Remarkably, transfection of Langerin cDNA into fibroblasts created a compact network of membrane structures with typical features of BG. Langerin is thus a potent inducer of membrane superimposition and zippering leading to BG formation. Our data suggest that induction of BG is a consequence of the antigen-capture function of Langerin, allowing routing into these organelles and providing access to a nonclassical antigen-processing pathway. | {
"name": "type II Ca2+-dependent lectin",
"type": "GeneOrGeneProduct"
} | {
"name": "mannose",
"type": "ChemicalEntity"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Bind",
"Association"
] | Bind |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a disease breast cancer and a variant 5382insC in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means that a genetic variant is linked to an increased risk of a disease. This includes cases where the variant is more common in those with the disease, causes abnormal gene expression or non-functionality leading to the disease, results in a disease due to a protein deficiency for which the variant is responsible, contributes to genetic susceptibility to the disease, or has a significant impact on the development of the disease.
'Negative_Correlation' indicates that the variant decreases the risk of the disease.
'Association' means that a genetic variant found in some patients is linked to a lower chance of getting the disease, or it makes them less likely to develop the disease. It also covers relation that don't fit into a positive/negative correlation category or relation that are not clearly defined.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[breast cancer,DiseaseOrPhenotypicFeature]' and '[5382insC,SequenceVariant]'.
- Title of the Paper: Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
- Abstract of the Paper: [We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. ]
Identify how '[breast cancer,DiseaseOrPhenotypicFeature]' and '[5382insC,SequenceVariant]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Positive_Correlation</s> | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. | We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. | {
"name": "breast cancer",
"type": "DiseaseOrPhenotypicFeature"
} | {
"name": "5382insC",
"type": "SequenceVariant"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Positive_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a disease breast cancer and a variant 4153delA in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means that a genetic variant is linked to an increased risk of a disease. This includes cases where the variant is more common in those with the disease, causes abnormal gene expression or non-functionality leading to the disease, results in a disease due to a protein deficiency for which the variant is responsible, contributes to genetic susceptibility to the disease, or has a significant impact on the development of the disease.
'Negative_Correlation' indicates that the variant decreases the risk of the disease.
'Association' means that a genetic variant found in some patients is linked to a lower chance of getting the disease, or it makes them less likely to develop the disease. It also covers relation that don't fit into a positive/negative correlation category or relation that are not clearly defined.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[breast cancer,DiseaseOrPhenotypicFeature]' and '[4153delA,SequenceVariant]'.
- Title of the Paper: Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
- Abstract of the Paper: [We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. ]
Identify how '[breast cancer,DiseaseOrPhenotypicFeature]' and '[4153delA,SequenceVariant]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Positive_Correlation</s> | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. | We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. | {
"name": "breast cancer",
"type": "DiseaseOrPhenotypicFeature"
} | {
"name": "4153delA",
"type": "SequenceVariant"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Positive_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a disease breast cancer and a variant C61G in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means that a genetic variant is linked to an increased risk of a disease. This includes cases where the variant is more common in those with the disease, causes abnormal gene expression or non-functionality leading to the disease, results in a disease due to a protein deficiency for which the variant is responsible, contributes to genetic susceptibility to the disease, or has a significant impact on the development of the disease.
'Negative_Correlation' indicates that the variant decreases the risk of the disease.
'Association' means that a genetic variant found in some patients is linked to a lower chance of getting the disease, or it makes them less likely to develop the disease. It also covers relation that don't fit into a positive/negative correlation category or relation that are not clearly defined.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[breast cancer,DiseaseOrPhenotypicFeature]' and '[C61G,SequenceVariant]'.
- Title of the Paper: Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
- Abstract of the Paper: [We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. ]
Identify how '[breast cancer,DiseaseOrPhenotypicFeature]' and '[C61G,SequenceVariant]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Positive_Correlation</s> | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. | We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. | {
"name": "breast cancer",
"type": "DiseaseOrPhenotypicFeature"
} | {
"name": "C61G",
"type": "SequenceVariant"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Positive_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a disease ovarian cancer and a variant 5382insC in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means that a genetic variant is linked to an increased risk of a disease. This includes cases where the variant is more common in those with the disease, causes abnormal gene expression or non-functionality leading to the disease, results in a disease due to a protein deficiency for which the variant is responsible, contributes to genetic susceptibility to the disease, or has a significant impact on the development of the disease.
'Negative_Correlation' indicates that the variant decreases the risk of the disease.
'Association' means that a genetic variant found in some patients is linked to a lower chance of getting the disease, or it makes them less likely to develop the disease. It also covers relation that don't fit into a positive/negative correlation category or relation that are not clearly defined.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[ovarian cancer,DiseaseOrPhenotypicFeature]' and '[5382insC,SequenceVariant]'.
- Title of the Paper: Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
- Abstract of the Paper: [We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. ]
Identify how '[ovarian cancer,DiseaseOrPhenotypicFeature]' and '[5382insC,SequenceVariant]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Positive_Correlation</s> | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. | We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. | {
"name": "ovarian cancer",
"type": "DiseaseOrPhenotypicFeature"
} | {
"name": "5382insC",
"type": "SequenceVariant"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Positive_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a disease ovarian cancer and a variant 4153delA in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means that a genetic variant is linked to an increased risk of a disease. This includes cases where the variant is more common in those with the disease, causes abnormal gene expression or non-functionality leading to the disease, results in a disease due to a protein deficiency for which the variant is responsible, contributes to genetic susceptibility to the disease, or has a significant impact on the development of the disease.
'Negative_Correlation' indicates that the variant decreases the risk of the disease.
'Association' means that a genetic variant found in some patients is linked to a lower chance of getting the disease, or it makes them less likely to develop the disease. It also covers relation that don't fit into a positive/negative correlation category or relation that are not clearly defined.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[ovarian cancer,DiseaseOrPhenotypicFeature]' and '[4153delA,SequenceVariant]'.
- Title of the Paper: Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
- Abstract of the Paper: [We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. ]
Identify how '[ovarian cancer,DiseaseOrPhenotypicFeature]' and '[4153delA,SequenceVariant]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Positive_Correlation</s> | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. | We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. | {
"name": "ovarian cancer",
"type": "DiseaseOrPhenotypicFeature"
} | {
"name": "4153delA",
"type": "SequenceVariant"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Positive_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a disease ovarian cancer and a variant C61G in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means that a genetic variant is linked to an increased risk of a disease. This includes cases where the variant is more common in those with the disease, causes abnormal gene expression or non-functionality leading to the disease, results in a disease due to a protein deficiency for which the variant is responsible, contributes to genetic susceptibility to the disease, or has a significant impact on the development of the disease.
'Negative_Correlation' indicates that the variant decreases the risk of the disease.
'Association' means that a genetic variant found in some patients is linked to a lower chance of getting the disease, or it makes them less likely to develop the disease. It also covers relation that don't fit into a positive/negative correlation category or relation that are not clearly defined.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[ovarian cancer,DiseaseOrPhenotypicFeature]' and '[C61G,SequenceVariant]'.
- Title of the Paper: Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
- Abstract of the Paper: [We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. ]
Identify how '[ovarian cancer,DiseaseOrPhenotypicFeature]' and '[C61G,SequenceVariant]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Positive_Correlation</s> | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. | We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. | {
"name": "ovarian cancer",
"type": "DiseaseOrPhenotypicFeature"
} | {
"name": "C61G",
"type": "SequenceVariant"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Positive_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a variant 5382insC and a disease breast-ovarian cancer syndrome in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means that a genetic variant is linked to an increased risk of a disease. This includes cases where the variant is more common in those with the disease, causes abnormal gene expression or non-functionality leading to the disease, results in a disease due to a protein deficiency for which the variant is responsible, contributes to genetic susceptibility to the disease, or has a significant impact on the development of the disease.
'Negative_Correlation' indicates that the variant decreases the risk of the disease.
'Association' means that a genetic variant found in some patients is linked to a lower chance of getting the disease, or it makes them less likely to develop the disease. It also covers relation that don't fit into a positive/negative correlation category or relation that are not clearly defined.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[5382insC,SequenceVariant]' and '[breast-ovarian cancer syndrome,DiseaseOrPhenotypicFeature]'.
- Title of the Paper: Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
- Abstract of the Paper: [We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. ]
Identify how '[5382insC,SequenceVariant]' and '[breast-ovarian cancer syndrome,DiseaseOrPhenotypicFeature]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Positive_Correlation</s> | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. | We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. | {
"name": "5382insC",
"type": "SequenceVariant"
} | {
"name": "breast-ovarian cancer syndrome",
"type": "DiseaseOrPhenotypicFeature"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Positive_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a variant 4153delA and a disease breast-ovarian cancer syndrome in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means that a genetic variant is linked to an increased risk of a disease. This includes cases where the variant is more common in those with the disease, causes abnormal gene expression or non-functionality leading to the disease, results in a disease due to a protein deficiency for which the variant is responsible, contributes to genetic susceptibility to the disease, or has a significant impact on the development of the disease.
'Negative_Correlation' indicates that the variant decreases the risk of the disease.
'Association' means that a genetic variant found in some patients is linked to a lower chance of getting the disease, or it makes them less likely to develop the disease. It also covers relation that don't fit into a positive/negative correlation category or relation that are not clearly defined.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[4153delA,SequenceVariant]' and '[breast-ovarian cancer syndrome,DiseaseOrPhenotypicFeature]'.
- Title of the Paper: Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
- Abstract of the Paper: [We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. ]
Identify how '[4153delA,SequenceVariant]' and '[breast-ovarian cancer syndrome,DiseaseOrPhenotypicFeature]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Positive_Correlation</s> | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. | We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. | {
"name": "4153delA",
"type": "SequenceVariant"
} | {
"name": "breast-ovarian cancer syndrome",
"type": "DiseaseOrPhenotypicFeature"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Positive_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a variant C61G and a disease breast-ovarian cancer syndrome in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means that a genetic variant is linked to an increased risk of a disease. This includes cases where the variant is more common in those with the disease, causes abnormal gene expression or non-functionality leading to the disease, results in a disease due to a protein deficiency for which the variant is responsible, contributes to genetic susceptibility to the disease, or has a significant impact on the development of the disease.
'Negative_Correlation' indicates that the variant decreases the risk of the disease.
'Association' means that a genetic variant found in some patients is linked to a lower chance of getting the disease, or it makes them less likely to develop the disease. It also covers relation that don't fit into a positive/negative correlation category or relation that are not clearly defined.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[C61G,SequenceVariant]' and '[breast-ovarian cancer syndrome,DiseaseOrPhenotypicFeature]'.
- Title of the Paper: Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
- Abstract of the Paper: [We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. ]
Identify how '[C61G,SequenceVariant]' and '[breast-ovarian cancer syndrome,DiseaseOrPhenotypicFeature]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Positive_Correlation</s> | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. | We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. | {
"name": "C61G",
"type": "SequenceVariant"
} | {
"name": "breast-ovarian cancer syndrome",
"type": "DiseaseOrPhenotypicFeature"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Positive_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a disease BRCA1 abnormalities and a variant 5382insC in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means that a genetic variant is linked to an increased risk of a disease. This includes cases where the variant is more common in those with the disease, causes abnormal gene expression or non-functionality leading to the disease, results in a disease due to a protein deficiency for which the variant is responsible, contributes to genetic susceptibility to the disease, or has a significant impact on the development of the disease.
'Negative_Correlation' indicates that the variant decreases the risk of the disease.
'Association' means that a genetic variant found in some patients is linked to a lower chance of getting the disease, or it makes them less likely to develop the disease. It also covers relation that don't fit into a positive/negative correlation category or relation that are not clearly defined.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[BRCA1 abnormalities,DiseaseOrPhenotypicFeature]' and '[5382insC,SequenceVariant]'.
- Title of the Paper: Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
- Abstract of the Paper: [We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. ]
Identify how '[BRCA1 abnormalities,DiseaseOrPhenotypicFeature]' and '[5382insC,SequenceVariant]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Positive_Correlation</s> | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. | We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. | {
"name": "BRCA1 abnormalities",
"type": "DiseaseOrPhenotypicFeature"
} | {
"name": "5382insC",
"type": "SequenceVariant"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Positive_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a disease BRCA1 abnormalities and a variant 4153delA in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means that a genetic variant is linked to an increased risk of a disease. This includes cases where the variant is more common in those with the disease, causes abnormal gene expression or non-functionality leading to the disease, results in a disease due to a protein deficiency for which the variant is responsible, contributes to genetic susceptibility to the disease, or has a significant impact on the development of the disease.
'Negative_Correlation' indicates that the variant decreases the risk of the disease.
'Association' means that a genetic variant found in some patients is linked to a lower chance of getting the disease, or it makes them less likely to develop the disease. It also covers relation that don't fit into a positive/negative correlation category or relation that are not clearly defined.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[BRCA1 abnormalities,DiseaseOrPhenotypicFeature]' and '[4153delA,SequenceVariant]'.
- Title of the Paper: Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
- Abstract of the Paper: [We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. ]
Identify how '[BRCA1 abnormalities,DiseaseOrPhenotypicFeature]' and '[4153delA,SequenceVariant]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Positive_Correlation</s> | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. | We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. | {
"name": "BRCA1 abnormalities",
"type": "DiseaseOrPhenotypicFeature"
} | {
"name": "4153delA",
"type": "SequenceVariant"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Positive_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a disease BRCA1 abnormalities and a variant C61G in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means that a genetic variant is linked to an increased risk of a disease. This includes cases where the variant is more common in those with the disease, causes abnormal gene expression or non-functionality leading to the disease, results in a disease due to a protein deficiency for which the variant is responsible, contributes to genetic susceptibility to the disease, or has a significant impact on the development of the disease.
'Negative_Correlation' indicates that the variant decreases the risk of the disease.
'Association' means that a genetic variant found in some patients is linked to a lower chance of getting the disease, or it makes them less likely to develop the disease. It also covers relation that don't fit into a positive/negative correlation category or relation that are not clearly defined.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[BRCA1 abnormalities,DiseaseOrPhenotypicFeature]' and '[C61G,SequenceVariant]'.
- Title of the Paper: Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
- Abstract of the Paper: [We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. ]
Identify how '[BRCA1 abnormalities,DiseaseOrPhenotypicFeature]' and '[C61G,SequenceVariant]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Positive_Correlation</s> | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. | We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. | {
"name": "BRCA1 abnormalities",
"type": "DiseaseOrPhenotypicFeature"
} | {
"name": "C61G",
"type": "SequenceVariant"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Positive_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a gene or protein BRCA1 and a disease breast cancers in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' here means that the relation between a gene and a disease is direct and increases the likelihood of the disease. This includes cases where too much protein causes the disease, removing the gene prevents the disease, or a side effect from the protein or drug results in the disease.
'Negative_Correlation' indicates that when a protein (or gene) is present, it helps to treat or prevent a disease. Conversely, the absence of this protein or the deactivation of its gene can lead to the disease.
'Association' is used to describe relation that don't clearly fall under categories like positive or negative correlation, or when the nature of the relation lack a clear description.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[BRCA1,GeneOrGeneProduct]' and '[breast cancers,DiseaseOrPhenotypicFeature]'.
- Title of the Paper: Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
- Abstract of the Paper: [We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. ]
Identify how '[BRCA1,GeneOrGeneProduct]' and '[breast cancers,DiseaseOrPhenotypicFeature]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Association</s> | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. | We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. | {
"name": "BRCA1",
"type": "GeneOrGeneProduct"
} | {
"name": "breast cancers",
"type": "DiseaseOrPhenotypicFeature"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Association |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a gene or protein BRCA1 and a disease ovarian cancer in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' here means that the relation between a gene and a disease is direct and increases the likelihood of the disease. This includes cases where too much protein causes the disease, removing the gene prevents the disease, or a side effect from the protein or drug results in the disease.
'Negative_Correlation' indicates that when a protein (or gene) is present, it helps to treat or prevent a disease. Conversely, the absence of this protein or the deactivation of its gene can lead to the disease.
'Association' is used to describe relation that don't clearly fall under categories like positive or negative correlation, or when the nature of the relation lack a clear description.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[BRCA1,GeneOrGeneProduct]' and '[ovarian cancer,DiseaseOrPhenotypicFeature]'.
- Title of the Paper: Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
- Abstract of the Paper: [We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. ]
Identify how '[BRCA1,GeneOrGeneProduct]' and '[ovarian cancer,DiseaseOrPhenotypicFeature]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Association</s> | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. | We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. | {
"name": "BRCA1",
"type": "GeneOrGeneProduct"
} | {
"name": "ovarian cancer",
"type": "DiseaseOrPhenotypicFeature"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Association |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a gene or protein BRCA1 and a disease BRCA1 abnormalities in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' here means that the relation between a gene and a disease is direct and increases the likelihood of the disease. This includes cases where too much protein causes the disease, removing the gene prevents the disease, or a side effect from the protein or drug results in the disease.
'Negative_Correlation' indicates that when a protein (or gene) is present, it helps to treat or prevent a disease. Conversely, the absence of this protein or the deactivation of its gene can lead to the disease.
'Association' is used to describe relation that don't clearly fall under categories like positive or negative correlation, or when the nature of the relation lack a clear description.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[BRCA1,GeneOrGeneProduct]' and '[BRCA1 abnormalities,DiseaseOrPhenotypicFeature]'.
- Title of the Paper: Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
- Abstract of the Paper: [We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. ]
Identify how '[BRCA1,GeneOrGeneProduct]' and '[BRCA1 abnormalities,DiseaseOrPhenotypicFeature]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Association</s> | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. | We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. | {
"name": "BRCA1",
"type": "GeneOrGeneProduct"
} | {
"name": "BRCA1 abnormalities",
"type": "DiseaseOrPhenotypicFeature"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Association |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a gene or protein BRCA1 and a disease breast-ovarian cancer in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' here means that the relation between a gene and a disease is direct and increases the likelihood of the disease. This includes cases where too much protein causes the disease, removing the gene prevents the disease, or a side effect from the protein or drug results in the disease.
'Negative_Correlation' indicates that when a protein (or gene) is present, it helps to treat or prevent a disease. Conversely, the absence of this protein or the deactivation of its gene can lead to the disease.
'Association' is used to describe relation that don't clearly fall under categories like positive or negative correlation, or when the nature of the relation lack a clear description.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[BRCA1,GeneOrGeneProduct]' and '[breast-ovarian cancer,DiseaseOrPhenotypicFeature]'.
- Title of the Paper: Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
- Abstract of the Paper: [We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. ]
Identify how '[BRCA1,GeneOrGeneProduct]' and '[breast-ovarian cancer,DiseaseOrPhenotypicFeature]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Association</s> | Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. | We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population. The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years. A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only. Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family. The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants. Mutations were found in 35 (53%) of the 66 families studied. All but one of the mutations were detected within the BRCA1 gene. BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only. The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome. Seven distinct mutations were identified; five of these occurred in two or more families. In total, recurrent mutations were found in 33 (94%) of the 35 families with detected mutations. Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively.. | {
"name": "BRCA1",
"type": "GeneOrGeneProduct"
} | {
"name": "breast-ovarian cancer",
"type": "DiseaseOrPhenotypicFeature"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Association |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a chemical levodopa and a disease dyskinesias in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means there's a direct link between a chemical and a disease. This includes cases where the chemical causes the disease, higher doses of the chemical increase disease risk, the disease raises the chemical's level in the body, there's a direct positive link between the chemical's level and disease risk, or exposure to the chemical during development affects disease susceptibility later on.
'Negative_Correlation' means there's an inverse relation between a chemical substance and a disease. This includes situations where the chemical or drug is used to treat the disease, the presence of the disease lowers the level of the chemical in the body, or the chemical or drug reduces the likelihood of the disease.
'Association' is used to describe relation that don't clearly fall under categories like positive or negative correlation, or when the nature of the relation lack a clear description.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[levodopa,ChemicalEntity]' and '[dyskinesias,DiseaseOrPhenotypicFeature]'.
- Title of the Paper: Apomorphine: an underutilized therapy for Parkinson's disease.
- Abstract of the Paper: [Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study. A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings. Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors. Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy. In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced dyskinesias. The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role. Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.]
Identify how '[levodopa,ChemicalEntity]' and '[dyskinesias,DiseaseOrPhenotypicFeature]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Positive_Correlation</s> | Apomorphine: an underutilized therapy for Parkinson's disease. | Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study. A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings. Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors. Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy. In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced dyskinesias. The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role. Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use. | {
"name": "levodopa",
"type": "ChemicalEntity"
} | {
"name": "dyskinesias",
"type": "DiseaseOrPhenotypicFeature"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Positive_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a chemical apomorphine and a chemical levodopa in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Drug_Interaction', 'Cotreatment', 'Conversion', 'Comparison', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' indicates that Chemical A increases the effectiveness of Chemical B. This includes making Chemical B more sensitive, enhancing its ability to treat or induce a disease, or boosting its role in gene activation.
'Negative_Correlation' means that Chemical A reduces the effectiveness and impact of Chemical B. This includes decreasing Chemical B's sensitivity, reducing its ability to treat or induce a disease, diminishing its side effects, and lowering the gene activation it causes.
'Drug_Interaction' is when two different drugs or chemicals affect each other's action in the body, happening when they are used at the same time.
'Cotreatment' means that two different drugs or chemicals are used in combination therapy.
'Conversion' means that one chemical changes into another chemical.
'Comparison' means that two different drugs or chemicals have some differences and similarities in their effects.
'Association' refers to the relation between two chemicals that do not fit into any specific, predefined categories of relations.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[apomorphine,ChemicalEntity]' and '[levodopa,ChemicalEntity]'.
- Title of the Paper: Apomorphine: an underutilized therapy for Parkinson's disease.
- Abstract of the Paper: [Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study. A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings. Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors. Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy. In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced dyskinesias. The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role. Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.]
Identify how '[apomorphine,ChemicalEntity]' and '[levodopa,ChemicalEntity]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Drug_Interaction', 'Cotreatment', 'Conversion', 'Comparison', 'Association']. [/INST]Negative_Correlation</s> | Apomorphine: an underutilized therapy for Parkinson's disease. | Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study. A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings. Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors. Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy. In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced dyskinesias. The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role. Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use. | {
"name": "apomorphine",
"type": "ChemicalEntity"
} | {
"name": "levodopa",
"type": "ChemicalEntity"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Drug_Interaction",
"Cotreatment",
"Conversion",
"Comparison",
"Association"
] | Negative_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a chemical apomorphine and a disease dyskinesias in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means there's a direct link between a chemical and a disease. This includes cases where the chemical causes the disease, higher doses of the chemical increase disease risk, the disease raises the chemical's level in the body, there's a direct positive link between the chemical's level and disease risk, or exposure to the chemical during development affects disease susceptibility later on.
'Negative_Correlation' means there's an inverse relation between a chemical substance and a disease. This includes situations where the chemical or drug is used to treat the disease, the presence of the disease lowers the level of the chemical in the body, or the chemical or drug reduces the likelihood of the disease.
'Association' is used to describe relation that don't clearly fall under categories like positive or negative correlation, or when the nature of the relation lack a clear description.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[apomorphine,ChemicalEntity]' and '[dyskinesias,DiseaseOrPhenotypicFeature]'.
- Title of the Paper: Apomorphine: an underutilized therapy for Parkinson's disease.
- Abstract of the Paper: [Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study. A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings. Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors. Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy. In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced dyskinesias. The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role. Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.]
Identify how '[apomorphine,ChemicalEntity]' and '[dyskinesias,DiseaseOrPhenotypicFeature]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Negative_Correlation</s> | Apomorphine: an underutilized therapy for Parkinson's disease. | Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study. A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings. Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors. Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy. In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced dyskinesias. The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role. Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use. | {
"name": "apomorphine",
"type": "ChemicalEntity"
} | {
"name": "dyskinesias",
"type": "DiseaseOrPhenotypicFeature"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Negative_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a chemical Apomorphine and a disease Parkinson's disease in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means there's a direct link between a chemical and a disease. This includes cases where the chemical causes the disease, higher doses of the chemical increase disease risk, the disease raises the chemical's level in the body, there's a direct positive link between the chemical's level and disease risk, or exposure to the chemical during development affects disease susceptibility later on.
'Negative_Correlation' means there's an inverse relation between a chemical substance and a disease. This includes situations where the chemical or drug is used to treat the disease, the presence of the disease lowers the level of the chemical in the body, or the chemical or drug reduces the likelihood of the disease.
'Association' is used to describe relation that don't clearly fall under categories like positive or negative correlation, or when the nature of the relation lack a clear description.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[Apomorphine,ChemicalEntity]' and '[Parkinson's disease,DiseaseOrPhenotypicFeature]'.
- Title of the Paper: Apomorphine: an underutilized therapy for Parkinson's disease.
- Abstract of the Paper: [Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study. A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings. Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors. Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy. In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced dyskinesias. The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role. Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.]
Identify how '[Apomorphine,ChemicalEntity]' and '[Parkinson's disease,DiseaseOrPhenotypicFeature]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Negative_Correlation</s> | Apomorphine: an underutilized therapy for Parkinson's disease. | Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study. A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings. Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors. Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy. In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced dyskinesias. The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role. Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use. | {
"name": "Apomorphine",
"type": "ChemicalEntity"
} | {
"name": "Parkinson's disease",
"type": "DiseaseOrPhenotypicFeature"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Negative_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a disease uterine sarcoma and a gene or protein Rab6c in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' here means that the relation between a protein or gene and a disease is direct and increases the likelihood of the disease. This includes cases where too much protein causes the disease, removing the gene prevents the disease, or a side effect from the protein or drug results in the disease.
'Negative_Correlation' indicates that when a protein (or drug) is present, it helps to treat or prevent a disease. Conversely, the absence of this protein or the deactivation of its gene can lead to the disease.
'Association' is used to describe relation that don't clearly fall under categories like positive or negative correlation, or when the nature of the relation lack a clear description.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[uterine sarcoma,DiseaseOrPhenotypicFeature]' and '[Rab6c,GeneOrGeneProduct]'.
- Title of the Paper: Rab6c, a new member of the rab gene family, is involved in drug resistance in MCF7/AdrR cells.
- Abstract of the Paper: [A new Rab6 homolog cDNA, Rab6c, was discovered by a hypermethylated DNA fragment probe that was isolated from a human multidrug resistant (MDR) breast cancer cell line, MCF7/AdrR, by the methylation sensitive-representational difference analysis (MS-RDA) technique. Rab6c was found to be under-expressed in MCF7/AdrR and MES-SA/Dx5 (a human MDR uterine sarcoma cell line) compared with their non-MDR parental cell lines. MCF7/AdrR cells expressing the exogenous Rab6c exhibited less resistance to several anti-cancer drugs, such as doxorubicin (DOX), taxol, vinblastine, and vincristine, than the control cells containing the empty vector. Flow cytometry experiments confirmed that the transfectants' diminished resistance to DOX was caused by increased drug accumulation induced by the exogenous Rab6c. These results indicate that Rab6c is involved in drug resistance in MCF7/AdrR cells.]
Identify how '[uterine sarcoma,DiseaseOrPhenotypicFeature]' and '[Rab6c,GeneOrGeneProduct]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Association</s> | Rab6c, a new member of the rab gene family, is involved in drug resistance in MCF7/AdrR cells. | A new Rab6 homolog cDNA, Rab6c, was discovered by a hypermethylated DNA fragment probe that was isolated from a human multidrug resistant (MDR) breast cancer cell line, MCF7/AdrR, by the methylation sensitive-representational difference analysis (MS-RDA) technique. Rab6c was found to be under-expressed in MCF7/AdrR and MES-SA/Dx5 (a human MDR uterine sarcoma cell line) compared with their non-MDR parental cell lines. MCF7/AdrR cells expressing the exogenous Rab6c exhibited less resistance to several anti-cancer drugs, such as doxorubicin (DOX), taxol, vinblastine, and vincristine, than the control cells containing the empty vector. Flow cytometry experiments confirmed that the transfectants' diminished resistance to DOX was caused by increased drug accumulation induced by the exogenous Rab6c. These results indicate that Rab6c is involved in drug resistance in MCF7/AdrR cells. | {
"name": "uterine sarcoma",
"type": "DiseaseOrPhenotypicFeature"
} | {
"name": "Rab6c",
"type": "GeneOrGeneProduct"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Association |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a gene or protein Rab6c and a chemical vincristine in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Bind', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means that a chemical leads to higher gene expression, or higher gene expression increases sensitivity to the chemical, or a gene variant exacerbates the chemical's side effects, or a gene causes an over-response to the chemical, or there is a positive interaction between two genes in any manner.
'Negative_Correlation' indicates that a chemical leads to reduced gene expression, or higher gene expression results in decreased sensitivity or resistance to the chemical, or a gene variant offers protection against the chemical's adverse effects, or a gene contributes to resistance against the chemical, or there exists a negative interaction between two genes in any form.
'Bind' means that a chemical either connects to a gene's promoter region or a protein acts as a receptor for that chemical.
'Association' is used to describe relation that don't clearly fall under categories like positive correlation, negative correlation and bind , or when the nature of the relation lack a clear description.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[Rab6c,GeneOrGeneProduct]' and '[vincristine,ChemicalEntity]'.
- Title of the Paper: Rab6c, a new member of the rab gene family, is involved in drug resistance in MCF7/AdrR cells.
- Abstract of the Paper: [A new Rab6 homolog cDNA, Rab6c, was discovered by a hypermethylated DNA fragment probe that was isolated from a human multidrug resistant (MDR) breast cancer cell line, MCF7/AdrR, by the methylation sensitive-representational difference analysis (MS-RDA) technique. Rab6c was found to be under-expressed in MCF7/AdrR and MES-SA/Dx5 (a human MDR uterine sarcoma cell line) compared with their non-MDR parental cell lines. MCF7/AdrR cells expressing the exogenous Rab6c exhibited less resistance to several anti-cancer drugs, such as doxorubicin (DOX), taxol, vinblastine, and vincristine, than the control cells containing the empty vector. Flow cytometry experiments confirmed that the transfectants' diminished resistance to DOX was caused by increased drug accumulation induced by the exogenous Rab6c. These results indicate that Rab6c is involved in drug resistance in MCF7/AdrR cells.]
Identify how '[Rab6c,GeneOrGeneProduct]' and '[vincristine,ChemicalEntity]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Bind', 'Association']. [/INST]Positive_Correlation</s> | Rab6c, a new member of the rab gene family, is involved in drug resistance in MCF7/AdrR cells. | A new Rab6 homolog cDNA, Rab6c, was discovered by a hypermethylated DNA fragment probe that was isolated from a human multidrug resistant (MDR) breast cancer cell line, MCF7/AdrR, by the methylation sensitive-representational difference analysis (MS-RDA) technique. Rab6c was found to be under-expressed in MCF7/AdrR and MES-SA/Dx5 (a human MDR uterine sarcoma cell line) compared with their non-MDR parental cell lines. MCF7/AdrR cells expressing the exogenous Rab6c exhibited less resistance to several anti-cancer drugs, such as doxorubicin (DOX), taxol, vinblastine, and vincristine, than the control cells containing the empty vector. Flow cytometry experiments confirmed that the transfectants' diminished resistance to DOX was caused by increased drug accumulation induced by the exogenous Rab6c. These results indicate that Rab6c is involved in drug resistance in MCF7/AdrR cells. | {
"name": "Rab6c",
"type": "GeneOrGeneProduct"
} | {
"name": "vincristine",
"type": "ChemicalEntity"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Bind",
"Association"
] | Positive_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a gene or protein Rab6c and a chemical vinblastine in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Bind', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means that a chemical leads to higher gene expression, or higher gene expression increases sensitivity to the chemical, or a gene variant exacerbates the chemical's side effects, or a gene causes an over-response to the chemical, or there is a positive interaction between two genes in any manner.
'Negative_Correlation' indicates that a chemical leads to reduced gene expression, or higher gene expression results in decreased sensitivity or resistance to the chemical, or a gene variant offers protection against the chemical's adverse effects, or a gene contributes to resistance against the chemical, or there exists a negative interaction between two genes in any form.
'Bind' means that a chemical either connects to a gene's promoter region or a protein acts as a receptor for that chemical.
'Association' is used to describe relation that don't clearly fall under categories like positive correlation, negative correlation and bind , or when the nature of the relation lack a clear description.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[Rab6c,GeneOrGeneProduct]' and '[vinblastine,ChemicalEntity]'.
- Title of the Paper: Rab6c, a new member of the rab gene family, is involved in drug resistance in MCF7/AdrR cells.
- Abstract of the Paper: [A new Rab6 homolog cDNA, Rab6c, was discovered by a hypermethylated DNA fragment probe that was isolated from a human multidrug resistant (MDR) breast cancer cell line, MCF7/AdrR, by the methylation sensitive-representational difference analysis (MS-RDA) technique. Rab6c was found to be under-expressed in MCF7/AdrR and MES-SA/Dx5 (a human MDR uterine sarcoma cell line) compared with their non-MDR parental cell lines. MCF7/AdrR cells expressing the exogenous Rab6c exhibited less resistance to several anti-cancer drugs, such as doxorubicin (DOX), taxol, vinblastine, and vincristine, than the control cells containing the empty vector. Flow cytometry experiments confirmed that the transfectants' diminished resistance to DOX was caused by increased drug accumulation induced by the exogenous Rab6c. These results indicate that Rab6c is involved in drug resistance in MCF7/AdrR cells.]
Identify how '[Rab6c,GeneOrGeneProduct]' and '[vinblastine,ChemicalEntity]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Bind', 'Association']. [/INST]Positive_Correlation</s> | Rab6c, a new member of the rab gene family, is involved in drug resistance in MCF7/AdrR cells. | A new Rab6 homolog cDNA, Rab6c, was discovered by a hypermethylated DNA fragment probe that was isolated from a human multidrug resistant (MDR) breast cancer cell line, MCF7/AdrR, by the methylation sensitive-representational difference analysis (MS-RDA) technique. Rab6c was found to be under-expressed in MCF7/AdrR and MES-SA/Dx5 (a human MDR uterine sarcoma cell line) compared with their non-MDR parental cell lines. MCF7/AdrR cells expressing the exogenous Rab6c exhibited less resistance to several anti-cancer drugs, such as doxorubicin (DOX), taxol, vinblastine, and vincristine, than the control cells containing the empty vector. Flow cytometry experiments confirmed that the transfectants' diminished resistance to DOX was caused by increased drug accumulation induced by the exogenous Rab6c. These results indicate that Rab6c is involved in drug resistance in MCF7/AdrR cells. | {
"name": "Rab6c",
"type": "GeneOrGeneProduct"
} | {
"name": "vinblastine",
"type": "ChemicalEntity"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Bind",
"Association"
] | Positive_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a gene or protein Rab6c and a chemical taxol in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Bind', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means that a chemical leads to higher gene expression, or higher gene expression increases sensitivity to the chemical, or a gene variant exacerbates the chemical's side effects, or a gene causes an over-response to the chemical, or there is a positive interaction between two genes in any manner.
'Negative_Correlation' indicates that a chemical leads to reduced gene expression, or higher gene expression results in decreased sensitivity or resistance to the chemical, or a gene variant offers protection against the chemical's adverse effects, or a gene contributes to resistance against the chemical, or there exists a negative interaction between two genes in any form.
'Bind' means that a chemical either connects to a gene's promoter region or a protein acts as a receptor for that chemical.
'Association' is used to describe relation that don't clearly fall under categories like positive correlation, negative correlation and bind , or when the nature of the relation lack a clear description.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[Rab6c,GeneOrGeneProduct]' and '[taxol,ChemicalEntity]'.
- Title of the Paper: Rab6c, a new member of the rab gene family, is involved in drug resistance in MCF7/AdrR cells.
- Abstract of the Paper: [A new Rab6 homolog cDNA, Rab6c, was discovered by a hypermethylated DNA fragment probe that was isolated from a human multidrug resistant (MDR) breast cancer cell line, MCF7/AdrR, by the methylation sensitive-representational difference analysis (MS-RDA) technique. Rab6c was found to be under-expressed in MCF7/AdrR and MES-SA/Dx5 (a human MDR uterine sarcoma cell line) compared with their non-MDR parental cell lines. MCF7/AdrR cells expressing the exogenous Rab6c exhibited less resistance to several anti-cancer drugs, such as doxorubicin (DOX), taxol, vinblastine, and vincristine, than the control cells containing the empty vector. Flow cytometry experiments confirmed that the transfectants' diminished resistance to DOX was caused by increased drug accumulation induced by the exogenous Rab6c. These results indicate that Rab6c is involved in drug resistance in MCF7/AdrR cells.]
Identify how '[Rab6c,GeneOrGeneProduct]' and '[taxol,ChemicalEntity]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Bind', 'Association']. [/INST]Positive_Correlation</s> | Rab6c, a new member of the rab gene family, is involved in drug resistance in MCF7/AdrR cells. | A new Rab6 homolog cDNA, Rab6c, was discovered by a hypermethylated DNA fragment probe that was isolated from a human multidrug resistant (MDR) breast cancer cell line, MCF7/AdrR, by the methylation sensitive-representational difference analysis (MS-RDA) technique. Rab6c was found to be under-expressed in MCF7/AdrR and MES-SA/Dx5 (a human MDR uterine sarcoma cell line) compared with their non-MDR parental cell lines. MCF7/AdrR cells expressing the exogenous Rab6c exhibited less resistance to several anti-cancer drugs, such as doxorubicin (DOX), taxol, vinblastine, and vincristine, than the control cells containing the empty vector. Flow cytometry experiments confirmed that the transfectants' diminished resistance to DOX was caused by increased drug accumulation induced by the exogenous Rab6c. These results indicate that Rab6c is involved in drug resistance in MCF7/AdrR cells. | {
"name": "Rab6c",
"type": "GeneOrGeneProduct"
} | {
"name": "taxol",
"type": "ChemicalEntity"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Bind",
"Association"
] | Positive_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a gene or protein Rab6c and a chemical doxorubicin in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Bind', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means that a chemical leads to higher gene expression, or higher gene expression increases sensitivity to the chemical, or a gene variant exacerbates the chemical's side effects, or a gene causes an over-response to the chemical, or there is a positive interaction between two genes in any manner.
'Negative_Correlation' indicates that a chemical leads to reduced gene expression, or higher gene expression results in decreased sensitivity or resistance to the chemical, or a gene variant offers protection against the chemical's adverse effects, or a gene contributes to resistance against the chemical, or there exists a negative interaction between two genes in any form.
'Bind' means that a chemical either connects to a gene's promoter region or a protein acts as a receptor for that chemical.
'Association' is used to describe relation that don't clearly fall under categories like positive correlation, negative correlation and bind , or when the nature of the relation lack a clear description.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[Rab6c,GeneOrGeneProduct]' and '[doxorubicin,ChemicalEntity]'.
- Title of the Paper: Rab6c, a new member of the rab gene family, is involved in drug resistance in MCF7/AdrR cells.
- Abstract of the Paper: [A new Rab6 homolog cDNA, Rab6c, was discovered by a hypermethylated DNA fragment probe that was isolated from a human multidrug resistant (MDR) breast cancer cell line, MCF7/AdrR, by the methylation sensitive-representational difference analysis (MS-RDA) technique. Rab6c was found to be under-expressed in MCF7/AdrR and MES-SA/Dx5 (a human MDR uterine sarcoma cell line) compared with their non-MDR parental cell lines. MCF7/AdrR cells expressing the exogenous Rab6c exhibited less resistance to several anti-cancer drugs, such as doxorubicin (DOX), taxol, vinblastine, and vincristine, than the control cells containing the empty vector. Flow cytometry experiments confirmed that the transfectants' diminished resistance to DOX was caused by increased drug accumulation induced by the exogenous Rab6c. These results indicate that Rab6c is involved in drug resistance in MCF7/AdrR cells.]
Identify how '[Rab6c,GeneOrGeneProduct]' and '[doxorubicin,ChemicalEntity]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Bind', 'Association']. [/INST]Positive_Correlation</s> | Rab6c, a new member of the rab gene family, is involved in drug resistance in MCF7/AdrR cells. | A new Rab6 homolog cDNA, Rab6c, was discovered by a hypermethylated DNA fragment probe that was isolated from a human multidrug resistant (MDR) breast cancer cell line, MCF7/AdrR, by the methylation sensitive-representational difference analysis (MS-RDA) technique. Rab6c was found to be under-expressed in MCF7/AdrR and MES-SA/Dx5 (a human MDR uterine sarcoma cell line) compared with their non-MDR parental cell lines. MCF7/AdrR cells expressing the exogenous Rab6c exhibited less resistance to several anti-cancer drugs, such as doxorubicin (DOX), taxol, vinblastine, and vincristine, than the control cells containing the empty vector. Flow cytometry experiments confirmed that the transfectants' diminished resistance to DOX was caused by increased drug accumulation induced by the exogenous Rab6c. These results indicate that Rab6c is involved in drug resistance in MCF7/AdrR cells. | {
"name": "Rab6c",
"type": "GeneOrGeneProduct"
} | {
"name": "doxorubicin",
"type": "ChemicalEntity"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Bind",
"Association"
] | Positive_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a gene or protein calcineurin and a chemical tacrolimus in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Bind', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means that a chemical leads to higher gene expression, or higher gene expression increases sensitivity to the chemical, or a gene variant exacerbates the chemical's side effects, or a gene causes an over-response to the chemical, or there is a positive interaction between two genes in any manner.
'Negative_Correlation' indicates that a chemical leads to reduced gene expression, or higher gene expression results in decreased sensitivity or resistance to the chemical, or a gene variant offers protection against the chemical's adverse effects, or a gene contributes to resistance against the chemical, or there exists a negative interaction between two genes in any form.
'Bind' means that a chemical either connects to a gene's promoter region or a protein acts as a receptor for that chemical.
'Association' is used to describe relation that don't clearly fall under categories like positive correlation, negative correlation and bind , or when the nature of the relation lack a clear description.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[calcineurin,GeneOrGeneProduct]' and '[tacrolimus,ChemicalEntity]'.
- Title of the Paper: End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.
- Abstract of the Paper: [BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic. Their use in orthotopic liver transplantation (OLTX) has dramatically improved success rates. Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD). This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients. METHODS: Patients receiving an OLTX only from June 1985 through December of 1994 who survived 6 months postoperatively were studied (n=834). Our prospectively collected database was the source of information. Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45. Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD. RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%). Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine. Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively. Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group. Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants. CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate. The development of ESRD decreases survival, particularly in those patients treated with dialysis only. Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome. However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD. New strategies for long-term immunosuppression may be needed to decrease this complication.]
Identify how '[calcineurin,GeneOrGeneProduct]' and '[tacrolimus,ChemicalEntity]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Bind', 'Association']. [/INST]Negative_Correlation</s> | End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. | BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic. Their use in orthotopic liver transplantation (OLTX) has dramatically improved success rates. Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD). This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients. METHODS: Patients receiving an OLTX only from June 1985 through December of 1994 who survived 6 months postoperatively were studied (n=834). Our prospectively collected database was the source of information. Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45. Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD. RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%). Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine. Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively. Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group. Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants. CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate. The development of ESRD decreases survival, particularly in those patients treated with dialysis only. Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome. However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD. New strategies for long-term immunosuppression may be needed to decrease this complication. | {
"name": "calcineurin",
"type": "GeneOrGeneProduct"
} | {
"name": "tacrolimus",
"type": "ChemicalEntity"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Bind",
"Association"
] | Negative_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a gene or protein calcineurin and a chemical cyclosporine in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Bind', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means that a chemical leads to higher gene expression, or higher gene expression increases sensitivity to the chemical, or a gene variant exacerbates the chemical's side effects, or a gene causes an over-response to the chemical, or there is a positive interaction between two genes in any manner.
'Negative_Correlation' indicates that a chemical leads to reduced gene expression, or higher gene expression results in decreased sensitivity or resistance to the chemical, or a gene variant offers protection against the chemical's adverse effects, or a gene contributes to resistance against the chemical, or there exists a negative interaction between two genes in any form.
'Bind' means that a chemical either connects to a gene's promoter region or a protein acts as a receptor for that chemical.
'Association' is used to describe relation that don't clearly fall under categories like positive correlation, negative correlation and bind , or when the nature of the relation lack a clear description.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[calcineurin,GeneOrGeneProduct]' and '[cyclosporine,ChemicalEntity]'.
- Title of the Paper: End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.
- Abstract of the Paper: [BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic. Their use in orthotopic liver transplantation (OLTX) has dramatically improved success rates. Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD). This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients. METHODS: Patients receiving an OLTX only from June 1985 through December of 1994 who survived 6 months postoperatively were studied (n=834). Our prospectively collected database was the source of information. Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45. Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD. RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%). Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine. Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively. Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group. Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants. CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate. The development of ESRD decreases survival, particularly in those patients treated with dialysis only. Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome. However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD. New strategies for long-term immunosuppression may be needed to decrease this complication.]
Identify how '[calcineurin,GeneOrGeneProduct]' and '[cyclosporine,ChemicalEntity]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Bind', 'Association']. [/INST]Negative_Correlation</s> | End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. | BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic. Their use in orthotopic liver transplantation (OLTX) has dramatically improved success rates. Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD). This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients. METHODS: Patients receiving an OLTX only from June 1985 through December of 1994 who survived 6 months postoperatively were studied (n=834). Our prospectively collected database was the source of information. Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45. Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD. RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%). Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine. Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively. Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group. Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants. CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate. The development of ESRD decreases survival, particularly in those patients treated with dialysis only. Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome. However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD. New strategies for long-term immunosuppression may be needed to decrease this complication. | {
"name": "calcineurin",
"type": "GeneOrGeneProduct"
} | {
"name": "cyclosporine",
"type": "ChemicalEntity"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Bind",
"Association"
] | Negative_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a disease hepatorenal syndrome and a chemical creatinine in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means there's a direct link between a chemical and a disease. This includes cases where the chemical causes the disease, higher doses of the chemical increase disease risk, the disease raises the chemical's level in the body, there's a direct positive link between the chemical's level and disease risk, or exposure to the chemical during development affects disease susceptibility later on.
'Negative_Correlation' means there's an inverse relation between a chemical substance and a disease. This includes situations where the chemical or drug is used to treat the disease, the presence of the disease lowers the level of the chemical in the body, or the chemical or drug reduces the likelihood of the disease.
'Association' is used to describe relation that don't clearly fall under categories like positive or negative correlation, or when the nature of the relation lack a clear description.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[hepatorenal syndrome,DiseaseOrPhenotypicFeature]' and '[creatinine,ChemicalEntity]'.
- Title of the Paper: End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.
- Abstract of the Paper: [BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic. Their use in orthotopic liver transplantation (OLTX) has dramatically improved success rates. Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD). This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients. METHODS: Patients receiving an OLTX only from June 1985 through December of 1994 who survived 6 months postoperatively were studied (n=834). Our prospectively collected database was the source of information. Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45. Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD. RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%). Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine. Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively. Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group. Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants. CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate. The development of ESRD decreases survival, particularly in those patients treated with dialysis only. Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome. However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD. New strategies for long-term immunosuppression may be needed to decrease this complication.]
Identify how '[hepatorenal syndrome,DiseaseOrPhenotypicFeature]' and '[creatinine,ChemicalEntity]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Positive_Correlation</s> | End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. | BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic. Their use in orthotopic liver transplantation (OLTX) has dramatically improved success rates. Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD). This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients. METHODS: Patients receiving an OLTX only from June 1985 through December of 1994 who survived 6 months postoperatively were studied (n=834). Our prospectively collected database was the source of information. Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45. Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD. RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%). Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine. Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively. Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group. Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants. CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate. The development of ESRD decreases survival, particularly in those patients treated with dialysis only. Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome. However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD. New strategies for long-term immunosuppression may be needed to decrease this complication. | {
"name": "hepatorenal syndrome",
"type": "DiseaseOrPhenotypicFeature"
} | {
"name": "creatinine",
"type": "ChemicalEntity"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Positive_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a chemical tacrolimus and a disease nephrotoxic in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means there's a direct link between a chemical and a disease. This includes cases where the chemical causes the disease, higher doses of the chemical increase disease risk, the disease raises the chemical's level in the body, there's a direct positive link between the chemical's level and disease risk, or exposure to the chemical during development affects disease susceptibility later on.
'Negative_Correlation' means there's an inverse relation between a chemical substance and a disease. This includes situations where the chemical or drug is used to treat the disease, the presence of the disease lowers the level of the chemical in the body, or the chemical or drug reduces the likelihood of the disease.
'Association' is used to describe relation that don't clearly fall under categories like positive or negative correlation, or when the nature of the relation lack a clear description.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[tacrolimus,ChemicalEntity]' and '[nephrotoxic,DiseaseOrPhenotypicFeature]'.
- Title of the Paper: End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.
- Abstract of the Paper: [BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic. Their use in orthotopic liver transplantation (OLTX) has dramatically improved success rates. Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD). This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients. METHODS: Patients receiving an OLTX only from June 1985 through December of 1994 who survived 6 months postoperatively were studied (n=834). Our prospectively collected database was the source of information. Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45. Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD. RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%). Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine. Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively. Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group. Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants. CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate. The development of ESRD decreases survival, particularly in those patients treated with dialysis only. Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome. However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD. New strategies for long-term immunosuppression may be needed to decrease this complication.]
Identify how '[tacrolimus,ChemicalEntity]' and '[nephrotoxic,DiseaseOrPhenotypicFeature]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Positive_Correlation</s> | End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. | BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic. Their use in orthotopic liver transplantation (OLTX) has dramatically improved success rates. Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD). This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients. METHODS: Patients receiving an OLTX only from June 1985 through December of 1994 who survived 6 months postoperatively were studied (n=834). Our prospectively collected database was the source of information. Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45. Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD. RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%). Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine. Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively. Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group. Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants. CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate. The development of ESRD decreases survival, particularly in those patients treated with dialysis only. Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome. However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD. New strategies for long-term immunosuppression may be needed to decrease this complication. | {
"name": "tacrolimus",
"type": "ChemicalEntity"
} | {
"name": "nephrotoxic",
"type": "DiseaseOrPhenotypicFeature"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Positive_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a disease CRF and a chemical creatinine in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means there's a direct link between a chemical and a disease. This includes cases where the chemical causes the disease, higher doses of the chemical increase disease risk, the disease raises the chemical's level in the body, there's a direct positive link between the chemical's level and disease risk, or exposure to the chemical during development affects disease susceptibility later on.
'Negative_Correlation' means there's an inverse relation between a chemical substance and a disease. This includes situations where the chemical or drug is used to treat the disease, the presence of the disease lowers the level of the chemical in the body, or the chemical or drug reduces the likelihood of the disease.
'Association' is used to describe relation that don't clearly fall under categories like positive or negative correlation, or when the nature of the relation lack a clear description.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[CRF,DiseaseOrPhenotypicFeature]' and '[creatinine,ChemicalEntity]'.
- Title of the Paper: End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.
- Abstract of the Paper: [BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic. Their use in orthotopic liver transplantation (OLTX) has dramatically improved success rates. Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD). This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients. METHODS: Patients receiving an OLTX only from June 1985 through December of 1994 who survived 6 months postoperatively were studied (n=834). Our prospectively collected database was the source of information. Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45. Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD. RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%). Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine. Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively. Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group. Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants. CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate. The development of ESRD decreases survival, particularly in those patients treated with dialysis only. Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome. However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD. New strategies for long-term immunosuppression may be needed to decrease this complication.]
Identify how '[CRF,DiseaseOrPhenotypicFeature]' and '[creatinine,ChemicalEntity]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Positive_Correlation</s> | End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. | BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic. Their use in orthotopic liver transplantation (OLTX) has dramatically improved success rates. Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD). This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients. METHODS: Patients receiving an OLTX only from June 1985 through December of 1994 who survived 6 months postoperatively were studied (n=834). Our prospectively collected database was the source of information. Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45. Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD. RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%). Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine. Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively. Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group. Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants. CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate. The development of ESRD decreases survival, particularly in those patients treated with dialysis only. Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome. However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD. New strategies for long-term immunosuppression may be needed to decrease this complication. | {
"name": "CRF",
"type": "DiseaseOrPhenotypicFeature"
} | {
"name": "creatinine",
"type": "ChemicalEntity"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Positive_Correlation |
<s>[INST]<<SYS>>
Your task is to determine the relationship between a chemical cyclosporine and a disease nephrotoxic in a medical text. Choose the correct relation from ['Positive_Correlation', 'Negative_Correlation', 'Association'], based only on the information provided in the text.The meanings of each relation type are as follows: 'Positive_Correlation' means there's a direct link between a chemical and a disease. This includes cases where the chemical causes the disease, higher doses of the chemical increase disease risk, the disease raises the chemical's level in the body, there's a direct positive link between the chemical's level and disease risk, or exposure to the chemical during development affects disease susceptibility later on.
'Negative_Correlation' means there's an inverse relation between a chemical substance and a disease. This includes situations where the chemical or drug is used to treat the disease, the presence of the disease lowers the level of the chemical in the body, or the chemical or drug reduces the likelihood of the disease.
'Association' is used to describe relation that don't clearly fall under categories like positive or negative correlation, or when the nature of the relation lack a clear description.
<</SYS>>
Examine the abstract and title of a medical research paper to determine the relationship between the entities '[cyclosporine,ChemicalEntity]' and '[nephrotoxic,DiseaseOrPhenotypicFeature]'.
- Title of the Paper: End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.
- Abstract of the Paper: [BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic. Their use in orthotopic liver transplantation (OLTX) has dramatically improved success rates. Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD). This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients. METHODS: Patients receiving an OLTX only from June 1985 through December of 1994 who survived 6 months postoperatively were studied (n=834). Our prospectively collected database was the source of information. Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45. Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD. RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%). Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine. Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively. Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group. Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants. CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate. The development of ESRD decreases survival, particularly in those patients treated with dialysis only. Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome. However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD. New strategies for long-term immunosuppression may be needed to decrease this complication.]
Identify how '[cyclosporine,ChemicalEntity]' and '[nephrotoxic,DiseaseOrPhenotypicFeature]' are related in the text, focusing on their interactions or associations. Then, select the most accurate relationship type from ['Positive_Correlation', 'Negative_Correlation', 'Association']. [/INST]Positive_Correlation</s> | End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. | BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic. Their use in orthotopic liver transplantation (OLTX) has dramatically improved success rates. Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD). This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients. METHODS: Patients receiving an OLTX only from June 1985 through December of 1994 who survived 6 months postoperatively were studied (n=834). Our prospectively collected database was the source of information. Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45. Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD. RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%). Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine. Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively. Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group. Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants. CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate. The development of ESRD decreases survival, particularly in those patients treated with dialysis only. Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome. However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD. New strategies for long-term immunosuppression may be needed to decrease this complication. | {
"name": "cyclosporine",
"type": "ChemicalEntity"
} | {
"name": "nephrotoxic",
"type": "DiseaseOrPhenotypicFeature"
} | [
"Positive_Correlation",
"Negative_Correlation",
"Association"
] | Positive_Correlation |
End of preview. Expand
in Data Studio
README.md exists but content is empty.
- Downloads last month
- 59